On our initial discovery that prion protein (PrP)-derived peptides were capable of capturing the pathogenic prion protein (PrP Sc ), we have been interested in how these peptides interact with PrP Sc . After screening peptides from the entire human PrP sequence, we found two peptides (PrP 19 -30 and PrP100-111) capable of binding full-length PrP Sc in plasma, a medium containing a complex mixture of other proteins including a vast excess of the normal prion protein (PrP C ). The limit of detection for captured PrP Sc was calculated to be 8 amol from a Ϸ10 5 -fold dilution of 10% (wt/vol) human variant Creutzfeldt-Jakob disease brain homogenate, with >3,800-fold binding specificity to PrP Sc over PrP C . Through extensive analyses, we show that positively charged amino acids play an important, but not exclusive, role in the interaction between the peptides and PrP Sc . Neither hydrophobic nor polar interactions appear to correlate with binding activity. The peptide-PrP Sc interaction was not sequence-specific, but amino acid composition affected binding. Binding occurs through a conformational domain that is only present in PrP Sc , is species-independent, and is not affected by proteinase K digestion. These and other findings suggest a mechanism by which cationic domains of PrP C may play a role in the recruitment of PrP C to PrP Sc .
T ransmissible spongiform encephalopathies are a group of neurodegenerative diseases affecting many mammalian species, including humans and cattle. Documented cases of prion disease indicate that transmissible spongiform encephalopathies can arise spontaneously [e.g., sporadic Creutzfeldt-Jakob disease (sCJD)], through genetic predisposition (e.g., familial CJD), through oral transmission [e.g., variant CJD (vCJD)], or through contaminated instruments or biomaterials (i.e., iatrogenetically) (1) . Since the vCJD outbreak in the United Kingdom, three cases of probable vCJD transmission from presymptomatic human blood donors have been reported (1) (2) (3) (4) . These three cases, coupled with the long incubation time of the disease, highlight the need for sensitive new diagnostics that can accurately screen presymptomatic samples.
Prion diseases are caused by pathogenic prion proteins (PrP Sc ), which are pathological conformers of the endogenous normal prion protein (PrP C ). Reagents capable of discriminating the two structurally distinct molecules are invaluable research tools. Unfortunately, the majority of all prion protein (PrP) antibodies recognize PrP C or both PrP C and PrP Sc . Despite not being PrP Sc -specific, recombinant antigen-binding fragments (Fabs) D13 (5) and D18 (6) have been shown to block the replication of the prion protein in vitro. By grafting the sequences corresponding to the epitopes recognized by these Fabs into a neutral antibody scaffold, reagents that bound preferentially to PrP Sc were generated (7) . In our own search for PrP Sc binding reagents, we discovered PrP-derived peptides that bound PrP Sc without the need of an antibody scaffold (9, ¶, ʈ). Since then, we have been interested in understanding the mechanism of how these peptides interact with PrP
Sc . In addition, we also performed a systematic search for other regions of the PrP protein sequence capable of binding PrP Sc and found four short PrP sequences that can discriminate between PrP Sc and PrP C . When coupled with a sandwich ELISA for detection, these peptide binding reagents create a sensitive assay that can detect PrP Sc in the nanoliter range of 10% (wt/vol) vCJD brain homogenate (BH). We believe this assay and our peptide-capturing reagents will be useful tools in studying PrP biology and as a basis for a diagnostic test for prions.
PrP 100 -111 is important for binding PrP Sc in plasma. As with the buffer assays, we did not detect captured PrP C . To begin understanding the mechanism of interaction between peptides and PrP Sc , we examined different physical properties of the PrP Sc -binding peptides (SI Table 2 ). Neither hydrophobicity (11) nor the number of polar residues appeared to correlate with binding activity, but charge seemed to correlate with binding activity. Comparing the sequences of PrP 19 -30 , PrP 100 -111 , PrP 154 -165 , and PrP 226 -237 , we noticed that PrP 19 -30 and PrP 100 -111 each contained four basic residues, whereas PrP 154 -165 and PrP 226 -237 contained two and one basic residue(s), respectively. To better understand the relationship between charge and binding, we plotted the amount of PrP Sc captured versus the net charge of each peptide sequence (Fig. 1C) . As expected, PrP 19 -30 and PrP 100 -111 are both strongly basic peptides with net charges of ϩ3.75 and ϩ3.84, respectively. PrP 154 -165 (ϩ1.84) and PrP 226 -237 (ϩ0.76) have more neutral net charges. From these results, binding of PrP Sc in plasma appears to require a higher positive net charge than in buffer. Because of their activity in plasma, we decided to concentrate our efforts on studying PrP 19 -30 and PrP 100 -111 .
Peptide-Coated Beads Outperform Grafted Antibody-Coated Beads.
Next, we compared both sequences in a peptide-coated beads format and when expressed in the antigen binding region of an IgG antibody that were also immobilized on paramagnetic beads as previously described (Fig. 1D) (Fig. 1E) . PrP-specific bands were only detected from infected BH with PrP 23-30 -coated beads. Bead capture followed by proteinase K (PK) digestion resulted in PrP Sc shifting to a lowermolecular-weight, protease-resistant core with the glycoform profile characteristic of the 263K strain of PrP Sc .
Amino Acid Charge and Sequence Effect. To help dissect the mechanism of how PrP 19 -30 and PrP 100 -111 interact with PrP Sc , we designed fine peptide walks of these peptides to identify amino acids essential for binding (Fig. 2) . Based on the results from overlapping peptides, the core sequence of PrP 19 -30 24 -35 (KRPKPGGWNTGG) already begins to show a decrease in signal (Fig. 2 A) (PrP [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] ) is the core sequence (Fig. 2B ). Both core sequences contain four positively charged amino acids, further indicating that strong positive charge is important for binding in plasma. By comparison, peptides containing three positively charged residues were all effective in capturing PrP Sc only in buffer ( Fig. 2  A and B) .
To further explore sequence specificity, we screened single alanine substitutions in the sequence of PrP [23] [24] [25] [26] [27] [28] [29] [30] and assessed their impact on PrP Sc binding (Fig. 2C ). In the presence of plasma, removal of any single positively charged amino acid reduced signal to background levels. However, mutating either one or both proline residue(s) did not affect binding. Therefore, any structure provided by the rigidity of the proline backbone does not appear to provide an important component to binding. Again, as was seen in the fine peptide walks, alanine-substituted peptides containing three basic residues were still able to bind PrP Sc in buffer. Finally, we tested whether the order of the amino acids was important for binding. PrP 19 -30 -Scramble (GKPGKCLKLPRG) and PrP 100 -111 -Scramble (HKTPNKSMKNKP; Fig. 2D ) were tested in the bead capture assay. These scrambled peptides performed very similarly to their unscrambled counterparts in both the buffer and plasma capture assays. This demonstrated that the order of the amino acids is not important in binding to PrP Sc . However, in the presence of plasma, there were significant differences between PrP 19 -30 and PrP 19 -30 -Scramble compared with PrP 100 -111 and PrP 100 -111 -Scramble. Despite both peptides having four positively charged residues and similar charge distributions, PrP 100 -111 captured Ϸ67% less PrP Sc than PrP 19 -30 -Scramble (P Ͼ 7.5 ϫ 10 Ϫ6 ; Fig. 2D ). These results show that uncharged amino acids, regardless of position, can also affect the binding interaction, suggesting amino acid composition is a component in the interaction between peptide and PrP Sc .
PrP23-30 Can Detect PrP Sc from Multiple Species.
To examine the sensitivity and specificity to PrP Sc of our assay, detection limits Measurements of PrP C in plasma were calculated on the basis of the signal from 370 nl of plasma. BH LoD are shown as nl of 10% (wt/vol) BH. LoD of captured PrP Sc was calculated based on a measurements taken with a spike of 50 nl of 10% (wt/vol) BH in 70 l plasma (assay), which is within the linear range of the standard curve, and then multiplied by the ratio of LoD (in nanoliters) per 50-nl spike. Infectious BH LoD was calculated on the basis of published ID 50 per gram of brain: human, 10 5 (12) to 10 7.8 (13) ; bovine, 10 6 to 10 7.67 (30) ; ovine, 10 6.6 (8); and hamster, 10 9.5 (10) . were determined for four different species: human, hamster, cattle, and sheep. Recombinant PrP (rPrP) proteins from each of the four species were used to define the analytical sensitivity of the ELISA and to generate standard curves for quantitating amounts of PrP (SI Fig. 4 ). The detection limit for the vCJD sample was found to be 1.9 nl of 10% wt/vol BH (i.e., final dilution factor of Ϸ10 4.7 ), which is equivalent to 0.02-12 ID 50 units of prion infectivity (Table 1) based on bioassay titers for sCJD (12, 13) or 8 amol (0.18 pg) based on the molecular weight of the human mature PrP protein (residues 23-231 at 22.3 kDa). Detection of the hamster 263K strain of PrP Sc was the most sensitive at a dilution factor of Ϸ10 5.3 , whereas bovine and ovine PrP Sc could be detected at Ϸ10 Ϫ4.6 and Ϸ10 Ϫ4.3 dilution, respectively. The calculated limits of detection for various species of rPrPs were from 0.8 to 2.3 pg, depending on the species and capturing antibody used in the ELISA (Table 1) . To understand the specificity of our peptides for PrP Sc in the plasma bead capture assay, we also measured PrP C levels in the normal plasma of each species and calculated concentrations from the matching species-specific standard curve with rPrP. Our measurement of human PrP C plasma levels (10 ng/ml) was in close agreement with those published by Völkel et al. (2.5-9.2 ng/ml) (14) . Also, our measurement for hamster PrP C plasma levels (8.7 ng/ml) was within the same range as those reported by MacGregor and Drummond (5.0-17 ng/ml) (15) . Given that 0.18 pg of PrP Sc was detected in 70 l of plasma containing Ͼ700 pg of PrP C , these data suggest that PrP [23] [24] [25] [26] [27] [28] [29] [30] binds PrP Sc over PrP C with a specificity of Ͼ3,800-fold.
PrP23-30 Recognizes a Structural Determinant of PrP Sc .
To determine whether the peptide-coated beads bound to a linear or a structural domain of PrP Sc , we denatured vCJD BH with increasing concentrations of guanidine hydrochloride (GdnHCl), and then used these samples in a bead capture assay with PrP 23-30 -coated beads (Fig. 3) . When plotted, the data points formed a single sigmoidal curve with one major transition. Because PrP [23] [24] [25] [26] [27] [28] [29] [30] is unable to bind denatured PrP Sc , the peptide likely recognizes a structural epitope on PrP Sc that is disrupted on treatment with chemical denaturant. This result was observed by using two different capture antibodies: CHIR-01, which recognizes the N-terminal region (Fig. 3A) , and CHIR-04, which recognizes the C-terminal region of PrP (Fig. 3B) . Because every curve contained one major transition, each can be defined by the GdnHCl concentration yielding half-maximal denaturation of PrP Sc (GdnHCl 1/2 ). The average GdnHCl 1/2 value for vCJD, using CHIR-01 as the capture antibody, was 1.60 M GdnHCl, whereas CHIR-04 produced an average value of 1.85 M GdnHCl. Analysis of sCJD produced curves shifted to the right of the vCJD profiles. With CHIR-01 as the capture antibody, the average GdnHCl 1/2 value was 2.44 M GdnHCl, and CHIR-04 produced an average value of 2.45 GdnHCl. The higher GdnHCl 1/2 values for sCJD, using two different capture antibodies, suggest that the structural motif recognized by PrP [23] [24] [25] [26] [27] [28] [29] [30] is more stable in this sCJD strain than for the vCJD sample.
Discussion
The work that we present here identifies the core sequences of two PrP domains (PrP [23] [24] [25] [26] [27] [28] [29] [30] and PrP 100 -111 ) that bind PrP Sc but not PrP C . For PrP [23] [24] [25] [26] [27] [28] [29] [30] , the specificity of binding PrP Sc over PrP C was Ͼ3,800-fold without using protease digestion. We found that the dominant characteristic for binding prion was charge, because neither hydrophobic nor polar interactions were correlated with binding activity. Interestingly, binding in plasma required a minimum of four basic residues (Figs. 1 and 2) . We did not observe sequence specificity, but the amino acid composition of the peptide was important for the binding interaction. Both PrP [23] [24] [25] [26] [27] [28] [29] [30] and PrP 100 -111 (data not shown) were capable of capturing PrP Sc from four different species.
Even though charge is very important in binding PrP Sc , it is clearly not the only determinant in the peptide binding interaction. We observed only a slight increase in capture efficiency when the peptides contained additional positively charged amino acids (data not shown). Also, we found peptides with very similar physical properties had very different PrP Sc -binding activities. For example, PrP 154 -165 binds PrP Sc in buffer, whereas the physically similar PrP 37-48 was ineffective in capturing PrP Sc (Fig.  1 A) . Finally, the amount of PrP Sc captured by PrP 19 -30 -Scramble was significantly higher than the amount captured by PrP 100 -111 , even though the two peptides are very similar in net charge and charge distribution. This suggests that the amino acid composition of PrP 100 -111 negatively affected binding (Fig. 2D) . Exploration of this complex issue will help elucidate more clearly the binding mechanism of these domains to PrP Sc .
Currently, the regions of PrP Sc that mediate binding and the exact mechanism of interaction between PrP Sc and these peptides is unknown. Because of the physical properties of these domains, we believe binding must take place against a negatively charged surface. However, the atomic structure of PrP Sc has eluded the community's efforts. Recently, projection and difference maps created by imaging uranyl acetate-stained 2D crystals have provided some insights into the possible structure of PrP Sc (16, 17) . One of the interesting aspects of these maps was the apparent binding of uranyl acetate to the center of a unit cell in the 2D crystal. Govaerts et al. (17) hypothesized that the left-handed ␤-helical structure exposed negatively charged carbonyl moieties along the protein backbone that coordinated with the positively charged uranyl ion. These carbonyl moieties may also provide a binding surface for PrP C through its two positively charged domains, subsequently assisting in the conversion of PrP C or recruitment of PrP C into PrP Sc aggregates. The two positively charged domains that we identified have been reported to be important for prion propagation through a variety of studies. For instance, transgenic mice carrying different N-terminal deletions, which contained the regions of mouse (Mo)PrP [23] [24] [25] [26] [27] [28] [29] [30] or MoPrP 99 -110 , had a delayed time until disease onset (18) (19) (20) . Furthermore, deleting MoPrP 23-88 enhanced the effect of the dominant-negative mutation MoQ218K in vitro (21) , and when combined with two point mutations in the that PrP [23] [24] [25] [26] [27] [28] [29] [30] and PrP 100 -111 can directly interact with PrP Sc . Thus, deletions of either domain would decrease recruitment of PrP C , whereas deletions in both domains would halt the conversion process, as supported by cell culture and transgenic mouse studies (18, 20) . However, these two sequences do not appear to participate in the homologous recognition between PrP C and PrP Sc , a determinant of the species barrier, because PrP [23] [24] [25] [26] [27] [28] [29] [30] and PrP 100 -111 are highly conserved and are both capable of binding to PrP Sc from multiple species.
Although cationic interactions may play a role in the interactions between PrP C and PrP Sc , the effect of this binding can enable or inhibit prion propagation. Intriguingly, positive charge has been implicated in familial CJD through the E200K mutation. An NMR structure of the mutant shows the generation of large patches of positive electrostatic potential at the surface of the mutant (22), possibly making the mutant PrP C more easily recruited by PrP Sc . In contrast, branched polyamines (polycations) have been shown to bind and partially disrupt the fibrillar structure of PrP Sc aggregates. As a result of treatment with these compounds, certain strains of PrP Sc became PK sensitive, and PrP Sc from chronically infected neuroblastoma cell lines could be cleared (23) . Another example of an inhibitory cationic interaction is the PrP C -mediated inhibition by the mutation of MoQ167, MoQ171, MoV214, and MoQ218 residues to the basic amino acid arginine, creating dominant-negative mutations (24) . This finding led the authors to suggest that the dominantnegative effect occurs through binding of the mutated PrP C to protein X, rendering it unavailable for prion propagation. In an alternative interpretation, the authors suggest that mutant PrP C has a higher affinity for PrP Sc , which would also lead to an inhibition of prion propagation. Consistent with the protective effect of basic residues is the observation that the polymorphisms of sheep R171 (25) and human K219 (26) confer resistance to prion disease. Therefore, understanding the mechanism of how the basic domains of PrP C interact with PrP Sc will enable the study of novel methods to interrupt prion propagation.
Development of antemortem prion tests is hampered by our incomplete knowledge of prion biology. One of the tissues being actively studied as a potential sample source is blood, because sample acquisition is relatively nonintrusive. Interestingly, plasma appeared to block the interaction of peptides with two positively charged residues. The cause of this ''plasma effect'' is currently unknown. One possible mechanism is that plasma components mask peptides from binding PrP Sc through nonspecific interactions (i.e., plasma is acting as a blocking agent). Alternatively, plasma components may bind PrP Sc , sequestering PrP Sc from binding the peptides. In light of our observation of a plasma effect, binding studies performed in simple defined buffer systems may have to be reevaluated. Another issue with plasma is its low level of infectivity, estimated to be Ͻ1 ID 50 per milliliter of whole blood (27) , which is at least 10 5 -fold less than the brain. Our assay is currently capable of detecting 8 amol of spiked brain-derived PrP Sc , which is equivalent to 0.02-12 ID 50 units based on bioassays of sCJD (12, 13) . We are assessing the detection of PrP Sc in endogenous blood components. In conclusion, we believe that our assay can effectively segregate PrP Sc from PrP C regardless of species and will provide a much-needed tool in the study of prion biology and the creation of an antemortem prion test.
Materials and Methods
Peptide Design. Overlapping peptides were designed to span the human PrP sequence from amino acids 1 to 253 (SI Table 2 ). Each peptide was 12 aa long, overlapping the next peptide by three residues and had the general structure of biotin-aminohexanoic acid-peptide-CONH 2 . Peptides PrP [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] and PrP 244-253 did not pass the manufacturer's quality control, and peptides PrP 172-183 and PrP 235-246 were insoluble in dimethylformamide.
Peptides for a fine walk of PrP 19 -30 were also 12 aa long, each offset by 1 aa toward the C terminus (Fig. 2 A) . Fine walk peptides for PrP 100 -111 were offset by 2 aa, starting from PrP 103 (Fig. 2B) . The general composition of these peptides was the same as above (biotin-aminohexanoic acid-peptide-CONH 2 ).
For the alanine scan, each residue of PrP [23] [24] [25] [26] [27] [28] [29] [30] was substituted with an alanine residue, except for the last two glycine residues (Fig. 2C) . In addition, a peptide that replaced both proline residues was also tested. These peptides were made by using three glycine residues as a linker (biotin-GGG-peptide-CONH 2 ).
All custom peptides were purchased from SynPep Corporation (Dublin, CA), SynBioSci Corporation (Livermore, CA), or Bio-Synthesis (Lewisville, TX), resuspended in dimethylformamide to a final concentration of 10 mM and stored at Ϫ20°C.
Bead Preparation. Biotinylated peptides were coated onto paramagnetic streptavidin-coated beads (Dynabeads M280-streptavidin; Invitrogen, San Diego, CA). Beads were initially rinsed, diluted into 10 vol of TBSTT [50 mM Tris⅐HCl (pH 7.5)/137 mM NaCl/1% Tween 20/1% Triton X-100], and incubated with 10 M biotinylated peptide for 1 h at 37°C while shaking. They were then washed four times with TBST [50 mM Tris⅐HCl (pH 7.5)/137 mM NaCl/0.05% Tween 20] , resuspended in 1 vol of TBST plus 0.05% NaN 3 , and stored at 4°C until needed.
Tissue Samples. Human sCJD (''Red,'' ''Green,'' and ''Yellow''), vCJD (''White'' and ''Blue''), and normal (''Clear'') BH were obtained from the National Institute for Biological Standards and Control (NIBSC) (United Kingdom) (28) . Whole units of normal human EDTA-plasma were purchased from SeraCare Life Sciences (West Bridgewater, MA). Normal sheep EDTAplasma, normal sheep brain (genotype AQ/AQ), and scrapie sheep brain (AQ/AQ) samples were a gift from Dr. Katherine O'Rourke (U.S. Department of Agriculture, Pullman, WA). Normal bovine and hamster EDTA-plasma was purchased from Innovative Research (Southfield, MI) and Bioreclamation (Hicksville, NY), respectively. Normal bovine obex were obtained from a local slaughterhouse (Petaluma, CA). Brainstems from cows infected with bovine spongiform encephalopathy were obtained from the Veterinary Laboratories Agency (United Kingdom). Normal and prion Syrian hamster BH were purchased from the Laboratory of Molecular Neurovirology at the Baltimore Research and Education Foundation (Baltimore, MD). Human, ovine, and bovine rPrP were purchased from AJ Roboscreen (Liepzig, Germany). Hamster rPrP protein was cloned, expressed, and purified.
Capturing and Detecting PrP Sc . BH spiked into buffer (TBSTT) or into 50-70% normal plasma with 1ϫ TBSTT (plasma-TBSTT) was incubated with 10 l (Ϸ6.5 ϫ 10 6 beads) of peptide-coated beads for 1 h at 37°C with constant shaking. Each reaction was 100 l (final volume). Afterward, the beads were washed four times with TBST, and bound molecules were eluted, reconditioned, and then detected by sandwich ELISA through incubation on capture plates coated with 2.5 g/ml PrP-specific antibody for 1 h at 37°C. Alkaline phosphatase (AP)-conjugated detection antibody was then added and incubated for 1 h at 37°C. After washing four times with TBST, 100 l of Lumiphos Plus substrate (Lumigen, Southfield, MI) was added, and results were read on a Luminoskan luminometer (Thermo Electron Corporation, Waltham, MA) by using an end-point assay, following each respective manufacturer's directions.
Determining Limit of Detection. For each species, a standard curve of rPrP was created by 3-fold serial dilutions of a 10 g/ml stock in TBST. PrP was captured on CHIR-02 (human and hamster PrP)-or CHIR-05 (bovine and ovine PrP)-coated plates and detected by CHIR-03-AP via a sandwich ELISA as described above. PrP C content for each species' plasma was measured similarly. Normal and infected species-specific BH were spiked into 70% plasma-TBSTT and subjected to PrP 23-30 -coated bead capture.
Levels of PrP from the plasma and bead capture assays from each species were calculated by using the linear portion of the standard curve generated from rPrP of the same species. Linear regression was used to fit the curves. Analyses of the limits of detection were performed following guidelines published by the Clinical and Laboratory Standards Institute (29) .
Grafted Antibodies. Grafted antibodies (Fig. 1D) were made and immobilized onto beads as described by Moroncini et al. (7) . Beads were allowed to mix with 1 l of 10% mixed BH (equal volumes of NIBSC Red, Green, and Blue) in 100 l of TBSTT. Beads were then washed four times with TBST, and bound PrP Sc was eluted and passively coated onto plates. Plate-bound PrP was incubated with CHIR-03 and detected by an AP-conjugated goat anti-mouse secondary antibody (Pierce, Rockford, IL).
Denaturation Profiles. For PrP [23] [24] [25] [26] [27] [28] [29] [30] bead capture assays, 600 nl of infectious 10% BH (Red sCJD or White vCJD) was denatured in GdnHCl solutions ranging in concentrations from 0 to 4 M for 1 h at room temperature. After denaturation, all samples were adjusted to a final concentration of 0.1 M GdnHCl in TBSTT and incubated with PrP 23-30 beads as described above. Captured material was detected by sandwich ELISA with either CHIR-01 or CHIR-04 as the capture antibody, and CHIR-02-AP was used as the detection antibody.
Western Blot Analysis. A total of 3 l of 10% Syrian hamster BH was either directly used for electrophoresis or subjected to bead capture. After samples were incubated with beads, the beads were washed with TBST and were resuspended in TBSS (1ϫ TBS, 2% Sarkosyl) for PK treatment. PK was added to the beads at a final concentration of 20 g/ml and at 50 g/ml for BH. Electrophoresis was performed by using 12% Bis-Tris NuPAGE gels (Invitrogen) in MOPS SDS running buffer (Invitrogen). After electrophoresis, proteins were transferred onto nitrocellulose. 3F4 (Covance, Princeton, NJ) was used as the primary antibody at a concentration of 0.1 g/ml. Immunopure goat anti-mouse secondary antibody (Pierce no. 31164) was used at a 1:10,000 dilution. Blots were developed by using Western Blue Stabilized Substrate for AP (Promega, Madison, WI). SeeBlue prestained markers (Invitrogen) were used as molecular weight standards.
Calculations. Net charge of the peptide sequence, discounting all other moieties (i.e., biotin, linkers, and C-terminal amidation), was calculated by Vector NTI Advance 9 (Invitrogen). ANOVA was performed in Microsoft (Redmond, WA) Excel 2000. Curve fitting for all graphs was performed by SigmaPlot, Version 9 (SysStat Software, Point Richmond, CA).
